Table 1. HrHPV type-specific prevalence rates in high-grade cervical intraepithelial neoplasia vs squamous cell carcinoma.
|
All infections
a
,b
|
Single infections
a
|
|||||||
|---|---|---|---|---|---|---|---|---|
| SCC | CIN2/3 | SCC∼>CIN2/3 | SCC | CIN2/3 | SCC∼>CIN2/3 | |||
| n=84 | n=139 | n=74 | n=126 | |||||
| Type | N (%) | N (%) | OR (95% CI) | P | N (%) | N (%) | OR (95% CI) | P |
| 16 | 58 (69.9) | 83 (59.7) | 1.5 (0.8–3.1) | 0.229 | 55 (74.3) | 75 (59.5) | 2.1 (1.0–4.5) | 0.065 |
| 18 | 10 (12.0) | 4 (2.9) | 8.3 (1.9–36) | 0.002 | 8 (10.8) | 3 (2.4) | 10 (2.0–52) | 0.005 |
| n16/n18 | 17 (20.5) | 51 (36.7) | 0.4 (0.2–0.8) | 0.009 | 11 (14.9) | 47 (37.3) | 0.2 (0.1–0.5) | 0.001 |
| 31 | 6 (7.2) | 18 (12.9) | 0.4 (0.1–1.5) | 0.145 | 3 (4.1) | 11 (8.7) | 0.5 (0.1–2.1) | 0.371 |
| 33 | 3 (3.6) | 8 (5.8) | 1.0 (0.2–4.6) | 0.959 | 1 (1.4) | 7 (5.6) | 0.4 (0.1–3.4) | 0.390 |
| 35 | 2 (2.4) | 5 (3.6) | 0.2 (0.1–3.3) | 0.272 | — | 3 (2.4) | — | — |
| 39 | 4 (4.8) | — | — | — | 1 (1.4) | — | — | — |
| 45 | 5 (6.0) | 6 (4.3) | 0.8 (0.1–6.1) | 0.850 | 4 (5.4) | 3 (2.4) | 0.6 (0.1–8.1) | 0.701 |
| 51 | — | 4 (2.9) | — | — | — | 3 (2.4) | — | — |
| 52 | — | 16 (11.5) | — | — | — | 14 (11.1) | — | — |
| 56 | 2 (2.4) | 1 (0.7) | 1.6 (0.1–46) | 0.815 | 1 (1.4) | 1 (0.8) | 1.7 (0.1–28) | 0.705 |
| 58 | 2 (2.4) | 7 (5.0) | 1.6 (0.1–11) | 0.652 | 1 (1.4) | 4 (3.2) | 0.6 (0.1–9.0) | 0.738 |
| 59 | — | 1 (0.7) | — | — | — | 1 (0.8) | — | — |
| 66 | — | 1 (0.7) | — | — | — | — | — | — |
| 68 | — | — | — | — | — | — | — | — |
CIN2/3=cervical intraepithelial neoplasia; HrHPV=high-risk human papillomavirus; SCC, squamous cell carcinoma.
Bold typeface indicates P<0.05.
a
Analyses are adjusted for age in 5-year strata.
b
Multiple and single infections combined. Analyses are adjusted for multiplicity of infection.